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Toward a Better Understanding of...
Activation of Dendritic 
Cell Subsets Following alum- or  
MPL-adjuvanted Vaccination
Kelly Hu
Mentor: Deepta Bhattacharya
An understanding of the mechanism of vaccine response is essential to elicit long-
term durable antibody protection through vaccination. Why is it that some vaccines 
achieve lifelong antibody titers, while others begin to lose antibody protection soon 
after vaccination? In our research, we wished to identify the dendritic cell (DC) 
subsets involved in the initiation of differential immune responses following alum- or 
MPL-adjuvanted vaccination. We hypothesized different DC subsets would respond 
to the different adjuvants, such that each subset is specialized to prime a specific set 
of T-cells. MPL-adjuvants would be more likely to activate CD24+ DCs to mediate 
Th1 cell-mediated immune responses, while alum-adjuvants would be more likely to 
activate DN-DCs to mediate Th2 antibody-mediated immune responses. In order to 
determine the efficiency of DC antigen presentation, in addition to DC activation, a 
special peptide antigen was injected into mice along with a particular adjuvant. Mice 
were subcutaneously injected into the flank with a solution of adjuvant and peptide, 
and DCs were isolated from the draining lymph nodes 24 hours post-immunization. 
Another set of mice was intraperitoneally injected with the same solution, and DCs were 
isolated from the spleen 24 hours post-immunization. Activated DCs were quantified by 
flow cytometry using DC subset-specific markers compared to unvaccinated controls. 
Preliminary data has so far suggested there are no differences in DC activation and/
or antigen presentation among the different DC subsets in response to injection with 
different adjuvants. 
